On July 27, 2026, Johnson & Johnson announced a proposed $5.5 billion resolution of the ovarian cancer talc claims consolidated in federal court in New Jersey and in related state court cases. The agreement is conditioned on at least 95 percent of remaining claimants participating, and it pays nothing until 2027. It does not resolve mesothelioma claims, which continue in state courts across the country.
What did Johnson & Johnson actually agree to?
The company disclosed the agreement in a securities filing on July 27, describing a $5.5 billion commitment to resolve the ovarian cancer talc litigation with the plaintiff firms leading the federal cases in New Jersey and related state court proceedings. By J&J’s count, the deal reaches roughly 76,000 claims. Lawyers on the plaintiffs’ negotiating committee have described the structure differently, as an uncapped agreement built on a tiered grid of claim values, with the total payout potentially running well above the announced figure.
That gap matters. The $5.5 billion number that ran in every headline is the company’s commitment, not a ceiling and not a final accounting. It is the number J&J chose to put in front of investors.
The agreement only takes effect if at least 95 percent of remaining claimants sign on. That threshold is not a technicality. It puts pressure on every individual claimant who might prefer to take her case to a jury, because a small group of holdouts can unwind the deal for everyone else. Structures like this are common in mass tort resolutions, and they consistently work in the defendant’s favor.
Why is the company settling now?
The timing is not accidental, and J&J has been explicit about why.
Most of the federal talc lawsuits are gathered in what courts call a multidistrict litigation, a system that consolidates thousands of similar cases before a single federal judge so that pretrial rulings happen once rather than case by case. The talc version of this, known on the docket as MDL 2738, sits in the District of New Jersey and is the largest active multidistrict litigation in the federal court system. It is not a class action. Each case remains a separate lawsuit with its own facts.
On July 22, 2026, that court ordered plaintiffs to show why the remaining pending talc claims should not be dismissed for failure to produce admissible expert testimony on specific causation, meaning proof tying talc use to a particular woman’s ovarian cancer. The order followed the withdrawal of two of the plaintiffs’ causation experts in bellwether cases. Four business days later, J&J announced the settlement and told investors it was confident it would have prevailed had the litigation continued.
Read that sequence carefully. A company that had just been handed the most favorable procedural ruling in a decade of this litigation chose to commit billions of dollars rather than press the advantage. Companies do not pay $5.5 billion to resolve claims they believe are worthless.
It is also worth remembering how J&J got here. Before this settlement, the company tried three separate times to route talc liability through the bankruptcy system, using a divisional merger structure widely known as the Texas Two-Step. Each attempt failed. The third, filed through a subsidiary called Red River Talc and carrying a roughly $9 billion price tag, was rejected by U.S. Bankruptcy Judge Christopher Lopez in Houston on March 31, 2025. J&J declined to appeal and returned to the tort system it had spent four years trying to avoid.
The settlement announced this week is what that system produced. It exists because courts refused to let a solvent company with a market capitalization in the hundreds of billions declare a subsidiary bankrupt to cap its liability.
Does this cover mesothelioma claims?
No. This agreement addresses ovarian cancer claims. J&J has said separately that it previously resolved roughly 95 percent of filed mesothelioma lawsuits, along with state consumer protection claims and disputes with its talc suppliers.
The distinction is important for anyone reading coverage of this settlement and trying to understand whether it applies to them.
The causation question that drove the July 22 order concerned whether plaintiffs could tie talc use to a particular woman’s ovarian cancer. Mesothelioma is a different matter entirely. Asbestos is the recognized cause of mesothelioma, and the scientific link is not seriously contested. Where talc is contaminated with asbestos, the path from product to disease is far more direct than in the ovarian cancer cases, and juries have consistently understood that.
In December 2025, a Ramsey County jury in Minnesota returned a $65.5 million verdict against Johnson & Johnson for a 37-year-old mother of three who developed peritoneal mesothelioma after her family used the company’s baby powder on her throughout childhood. The entire award was compensatory. In June 2026, the court denied J&J’s motion for a new trial and let the verdict stand. That track is still moving.
Our ongoing coverage of the J&J talc litigation
- Minnesota Jury Orders Johnson & Johnson to Pay $65.5 Million in Talc Cancer Lawsuit
- Johnson & Johnson Talc Bankruptcy Rejected
- Johnson & Johnson’s $9 Billion Talc Bankruptcy Settlement Under Scrutiny as Trial Concludes
- What Is the Texas Two-Step Bankruptcy Strategy?
- FDA Withdraws Talc-Asbestos Testing Rule: What It Means for Consumer Safety and Legal Claims
- FDA’s Proposed Asbestos Testing Rule for Talc in Cosmetics
How much is J&J paying, and when?
Not this year. The company told investors the first payment will be no more than $3 billion in 2027, with no additional payments due before 2028.
Johnson & Johnson generates roughly $90 billion in annual revenue. The first installment of this settlement, arriving more than a year after the announcement, amounts to a small fraction of a single year’s earnings, spread across tens of thousands of families. Many of the people covered by this agreement are living with terminal illness. Some have been waiting since the first talc filings a decade ago, through three bankruptcy attempts that froze their cases for years at a time.
Investors understood the deal well enough. J&J shares rose more than two percent on the announcement.
The company has not admitted that its talc products caused anyone’s cancer, and it continues to maintain that they are safe. It discontinued talc-based baby powder in the United States and Canada in 2020 and worldwide in 2023.
What this means for families still weighing their options
If you or someone in your family was diagnosed with ovarian cancer after long-term use of talc-based powder, this settlement may affect your claim, and the participation threshold means the decision has a deadline attached to it. Terms are still being finalized, and the value assigned to an individual claim depends on facts specific to that case.
If the diagnosis is mesothelioma, this settlement does not apply. Talc mesothelioma cases have been handled separately and continue to be tried in state courts. Exposure history matters a great deal in these cases, and it is not always obvious. Talc appears in far more products than baby powder, including cosmetics, body powders, and industrial applications, and many people with mesothelioma also carry occupational or household asbestos exposure that a full case review would identify.
What this week’s announcement confirms is that Johnson & Johnson could not make this litigation go away through bankruptcy court, and that it was willing to commit billions rather than keep trying cases in front of juries.
Anyone diagnosed with mesothelioma or ovarian cancer after using talc-based products can speak with an attorney experienced in asbestos and talc litigation to understand what options may still be available.
